India has made significant strides in pharmaceutical advancements with the launch of two innovative drugs: Lormalzi (donanemab) from Eli Lilly, the first drug targeting Alzheimer’s disease directly, and Tecentriq SC from Roche, a subcutaneous lung cancer immunotherapy. Lormalzi, priced at ₹91,688 per vial, is designed for patients diagnosed at the earliest stages of Alzheimer’s, aiming to clear amyloid plaques from the brain. However, it is only approved for mild cognitive impairment or mild dementia, necessitating a shift in diagnosis timing for many Indian families. Meanwhile, Tecentriq SC, costing ₹3.70 lakh per vial, offers the same therapeutic effects as its intravenous counterpart but with a significantly reduced administration time of just seven minutes. This change not only enhances patient comfort but also alleviates the burden on healthcare facilities. Despite these advancements, both treatments highlight the importance of early diagnosis and come with potential side effects that require careful patient management. Experts stress the need for improved access, insurance coverage, and patient assistance programs to ensure that these innovations benefit a broader population in India.